BiondVax's Universal Influenza Vaccine Has Blockbuster Potential Seeking Alpha, 25 Feb 2016 We are initiating coverage of BiondVax Pharmaceuticals, Ltd. (NASDAQ: BVXV ) with a Buy rating and a $17.00 price target.